Skip to main content
Year archive

Xbrane Biopharma — 2020 filings

All 62 regulatory filings released by Xbrane Biopharma (XBRANE) in 2020, sourced directly from the official regulator.

62 Filings
2020 Period
2020 filings (62)
Filing Released Lang
Nina Ivers joins Xbrane Biopharma as Head of HR
Board/Management Information
2020-12-16 English
Nina Ivers börjar på Xbrane Biopharma som HR-chef
Board/Management Information
2020-12-16 Swedish
Change of number of shares and votes in Xbrane
Share Issue/Capital Change
2020-11-30 English
Förändrat antal aktier och röster i Xbrane
Share Issue/Capital Change
2020-11-30 Swedish
Xbrane Biopharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issues completed on November 11 2020
Report Publication Announcement
2020-11-16 English
Xbrane Biopharma offentliggör prospekt avseende upptagande till handel av aktier på Nasdaq Stockholm i samband med en riktad nyemission som genomfördes 11 november 2020
Capital/Financing Update
2020-11-16 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-13 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report 9M 2020
2020-11-13 English
Xbrane Biopharma has completed a directed share issue of approximately SEK 200 million
Share Issue/Capital Change
2020-11-11 English
Xbrane Biopharma har genomfört en riktad nyemission på cirka 200 MSEK
Share Issue/Capital Change
2020-11-11 Swedish
Xbrane Biopharma announces intention to carry out a directed share issue
Capital/Financing Update
2020-11-11 English
Xbrane Biopharma offentliggör avsikt att genomföra en riktad nyemission av aktier
Share Issue/Capital Change
2020-11-11 Swedish
Xbrane Biopharma meddelar att den sista patienten i den registreringsgrundande fas III-studien XPLORE har rekryterats
Regulatory Filings
2020-11-11 Swedish
Xbrane announces that last patient has been enrolled into the pivotal phase III trial XPLORE
Regulatory Filings
2020-11-11 English
Xbrane Biopharma presenterar valberedning
Board/Management Information
2020-10-30 Swedish
Xbrane Biopharma presents Nomination Committee
AGM Information
2020-10-30 English
Ny interim CFO i Xbrane Biopharma AB (publ)
Board/Management Information
2020-09-28 Swedish
New Interim CFO in Xbrane Biopharma AB (publ)
Board/Management Information
2020-09-28 English
Announcement from the extra general meeting in Xbrane Biopharma
AGM Information
2020-09-22 English
Kommuniké från extra bolagsstämma i Xbrane Biopharma
AGM Information
2020-09-22 Swedish
Kallelse till extra bolagsstämma i Xbrane Biopharma AB
AGM Information
2020-08-21 Swedish
Notice of extra general meeting in Xbrane Biopharma AB
AGM Information
2020-08-21 English
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-08-21 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-08-21 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2020-07-17 English
Susanna Helgesen (CFO) leaves Xbrane
Board/Management Information
2020-07-10 English
Susanna Helgesen (CFO) lämnar Xbrane
Board/Management Information
2020-07-10 Swedish
Change of number of shares and votes in Xbrane
Share Issue/Capital Change
2020-06-30 English
Förändrat antal aktier och röster i Xbrane
Declaration of Voting Results & Voting Rights Announcements
2020-06-30 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-06-04 English
Change of number of shares and votes in Xbrane
Share Issue/Capital Change
2020-05-29 English
Förändrat antal aktier och röster i Xbrane
Share Issue/Capital Change
2020-05-29 Swedish
Xbrane publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issues
Report Publication Announcement
2020-05-28 English
Xbrane offentliggör prospekt för upptagande av aktier på Nasdaq Stockholm i samband med en riktad nyemission
Report Publication Announcement
2020-05-28 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-22 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-20 English
Xbrane has completed a directed share issue and thereby raises approximately SEK 146 million
Share Issue/Capital Change
2020-05-20 English
Xbrane har genomfört en riktad nyemission av aktier om cirka 146 MSEK
Share Issue/Capital Change
2020-05-20 Swedish
Xbrane intends to carry out a directed share issue through an accelerated book building process
Share Issue/Capital Change
2020-05-19 English
Xbrane offentliggör avsikt att genomföra en riktad nyemission av aktier genom ett accelererat bookbuilding-förfarande
Share Issue/Capital Change
2020-05-19 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-19 Swedish
Announcement from Xbrane Biopharma's annual general meeting
AGM Information
2020-05-14 English
Kommuniké från årsstämman i Xbrane Biopharma
AGM Information
2020-05-14 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-13 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-13 English
Xbrane och STADA ingår partnerskap med Bausch + Lomb för kommersialisering av Xlucane i USA och Kanada
Regulatory Filings
2020-05-06 Swedish
Xbrane and STADA partner with Bausch + Lomb for commercialization of Xlucane in the United States and Canada
M&A Activity
2020-05-06 English
Audit Report / Information 2019
Audit Report / Information FY 2019
2020-04-16 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-16 English
Notice of annual general meeting in Xbrane Biopharma AB
AGM Information
2020-04-15 English
Kallelse till årsstämma i Xbrane Biopharma AB
AGM Information
2020-04-15 Swedish
Xlucane är fortfarande på väg mot regulatoriskt godkännande innan Lucentis® förlorar patentskyddet i juli 2022 trots påverkan av Covid-19 på fas III-studien Xplore
Regulatory Filings
2020-04-02 Swedish
Xlucane is still on track towards regulatory approval ahead of Lucentis® patent expiration in EU July 2022 despite the impact of COVID-19 on the phase III-study Xplore
Regulatory Filings Q3 2020
2020-04-02 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q4 2019
2020-02-28 Swedish
Audit Report / Information 2019
Audit Report / Information FY 2019
2020-02-28 English
Maris Hartmanis declines re-election for 2020
Board/Management Information
2020-02-21 English
Maris Hartmanis ställer inte upp för omval 2020
Board/Management Information
2020-02-21 Swedish
Xbrane Biopharma förstärker koncernledningen i syfte att förbereda bolaget inför kommersialisering av sina biosimilarer
Board/Management Information
2020-02-21 Swedish
Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars
Board/Management Information
2020-02-21 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-01-24 English
Finchimica, parent company of Spherotide contract manufacturer ICI in Italy, enters into bankruptcy proceeding
Regulatory Filings
2020-01-17 English
Finchimica, moderbolag till Spherotides kontraktstillverkare ICI i Italien, har inlett konkursförfarande
Regulatory Filings
2020-01-17 Swedish